Study of GS-0272 in Participants With Rheumatoid Arthritis
← catalyst calendarSponsored by Gilead Sciences (industry) · GILD — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
55actual
Sites
24
Countries
Georgia, Moldova, South Korea +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Study terminated due to lack of efficacy.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-28 | actual | When the study began enrolling |
| Primary completion | 2026-05-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-11 | actual | The whole study's end, after follow-up |
| First posted | 2023-09-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Rheumatoid Arthritis
Interventions
- Drug: GS-0272
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Experiencing Adverse Events (AEs)
measured First dose up to Week 12 plus 70 days
Percentage of Participants Experiencing Serious Adverse Events (SAEs)
measured First dose up to Week 12 plus 70 days
Percentage of Participants With Laboratory Abnormalities
measured First dose up to Week 12 plus 70 days
Pharmacokinetics (PK) of GS-0272: AUCtau
measured Day 1 predose through Day 197
PK of GS-0272: Cmax
measured Day 1 predose through Day 197
PK of GS-0272: Tmax
measured Day 1 predose through Day 197
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed